Premium
A New Era of Cardiac Cell Therapy: Opportunities and Challenges
Author(s) -
Huang Ke,
Hu Shiqi,
Cheng Ke
Publication year - 2019
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201801011
Subject(s) - regeneration (biology) , myocardial infarction , regenerative medicine , paracrine signalling , biocompatible material , medicine , cell therapy , cardiac cell , intensive care medicine , neuroscience , risk analysis (engineering) , stem cell , cardiology , biology , biomedical engineering , microbiology and biotechnology , receptor
Myocardial infarction (MI), caused by coronary heart disease (CHD), remains one of the most common causes of death in the United States. Over the last few decades, scientists have invested considerable resources on the study and development of cell therapies for myocardial regeneration after MI. However, due to a number of limitations, they are not yet readily available for clinical applications. Mounting evidence supports the theory that paracrine products are the main contributors to the regenerative effects attributed to these cell therapies. The next generation of cell‐based MI therapies will identify and isolate cell products and derivatives, integrate them with biocompatible materials and technologies, and use them for the regeneration of damaged myocardial tissue. This review discusses the progress made thus far in pursuit of this new generation of cell therapies. Their fundamental regenerative mechanisms, their potential to combine with other therapeutic products, and their role in shaping new clinical approaches for heart tissue engineering, are addressed.